Positive News Sentiment NASDAQ:URGN UroGen Pharma Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. $8.11 -0.07 (-0.86%) (As of 07/5/2022 03:59 PM ET) Add Compare Share Today's Range$8.11▼$8.5250-Day Range$5.12▼$8.3552-Week Range$4.85▼$19.66Volume3,468 shsAverage Volume249,856 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice Target$19.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability UroGen Pharma MarketRank™ ForecastAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside134.3% Upside$19.00 Price TargetShort InterestBearish11.35% of Float Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews SentimentN/AInsider TradingSelling Shares$1,681 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.83) to ($3.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.2.33 out of 5 starsMedical Sector183rd out of 1,428 stocksPharmaceutical Preparations Industry79th out of 680 stocks 3.3 Analyst's Opinion Consensus RatingUroGen Pharma has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, UroGen Pharma has a forecasted upside of 134.3% from its current price of $8.11.Amount of Analyst CoverageUroGen Pharma has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted11.35% of the float of UroGen Pharma has been sold short.Short Interest Ratio / Days to CoverUroGen Pharma has a short interest ratio ("days to cover") of 10.6, which indicates bearish sentiment.Change versus previous monthShort interest in UroGen Pharma has recently decreased by 10.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUroGen Pharma does not currently pay a dividend.Dividend GrowthUroGen Pharma does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUroGen Pharma has received a 70.26% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Other cancer medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for UroGen Pharma is -1.33. Previous Next 3.3 News and Social Media Coverage News SentimentUroGen Pharma has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for UroGen Pharma this week, compared to 1 article on an average week.MarketBeat Follows3 people have added UroGen Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, UroGen Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,681.00 in company stock.Percentage Held by Insiders12.80% of the stock of UroGen Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for UroGen Pharma are expected to grow in the coming year, from ($4.83) to ($3.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of UroGen Pharma is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of UroGen Pharma is -1.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUroGen Pharma has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive URGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for UroGen Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address About UroGen Pharma (NASDAQ:URGN) StockUroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.Read More URGN Stock News HeadlinesJune 24, 2022 | americanbankingnews.comContrasting UroGen Pharma (NASDAQ:URGN) & Shattuck Labs (NASDAQ:STTK)June 9, 2022 | finance.yahoo.comDo Institutions Own UroGen Pharma Ltd. (NASDAQ:URGN) Shares?May 18, 2022 | finance.yahoo.comUroGen Pharma to Present at Upcoming Investor ConferencesMay 16, 2022 | finance.yahoo.comUroGen Highlights New Data Presented at AUA that Adds to the Evidence Supporting In-Office Nephrostomy Tube Administration of JELMYTO®, the only Non-Surgical, Kidney-Sparing Treatment for Adults with Low Grade Upper Tract Urothelial CancerMay 13, 2022 | finance.yahoo.comUroGen Pharma Highlights Data Presentations at the 2022 American Urological Association Annual MeetingMay 10, 2022 | seekingalpha.comUroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2022 Results - Earnings Call TranscriptMay 10, 2022 | investing.comUroGen Pharma Posts Smaller Q1 LossMay 10, 2022 | finance.yahoo.comPhathom Pharmaceuticals Reports First Quarter 2022 Results and Provides Recent Clinical, Regulatory, and Business UpdatesMay 10, 2022 | finance.yahoo.comUroGen Pharma Reports First Quarter 2022 Financial Results and Recent Corporate DevelopmentsMay 3, 2022 | finance.yahoo.comUroGen Pharma to Report First Quarter 2022 Financial Results on Tuesday, May 10, 2022April 27, 2022 | seekingalpha.comUroGen wins Buy rating at Berenberg on potential in bladder cancerMarch 29, 2022 | seekingalpha.comUroGen Pharma gets FDA nod to begin phase 1 trial of UGN-301 for bladder cancerMarch 29, 2022 | finance.yahoo.comUroGen Announces FDA Clearance of IND Application for the Investigational Immunotherapy UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder CancerMarch 24, 2022 | seekingalpha.comPhathom Pharmaceuticals names UroGen's Henderson as new CFOMarch 22, 2022 | markets.businessinsider.comUroGen Pharma earnings preview: what Wall Street is expectingMarch 22, 2022 | benzinga.comUroGen Pharma's Return On Capital Employed OverviewMarch 21, 2022 | finance.yahoo.comUroGen Pharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Corporate DevelopmentsMarch 18, 2022 | benzinga.comHow To Attend UroGen Pharma Q4 2021 Earnings Conference CallMarch 17, 2022 | benzinga.com5URGN : UroGen Pharma Q4 2021 Earnings Conference Call On March 21, 2...March 9, 2022 | benzinga.comEarnings Outlook For UroGen PharmaMarch 8, 2022 | finance.yahoo.comUroGen Secures $100 Million Non-Dilutive Term Loan Financing with Pharmakon Advisors Allowing Funding to Cash Flow BreakevenMarch 1, 2022 | finance.yahoo.comUroGen Submits Investigational New Drug Application Supporting Planned Phase 1 Clinical Study of UGN-301 (zalifrelimab) Intravesical Solution in Recurrent Non-Muscle Invasive Bladder CancerMarch 1, 2022 | finance.yahoo.comRhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Tops Revenue EstimatesFebruary 28, 2022 | finance.yahoo.comUroGen Pharma to Participate in Panel Discussion at Cowen 42nd Annual Healthcare ConferenceFebruary 10, 2022 | finance.yahoo.comUroGen Announces Data that Shows In-Office Nephrostomy Tube Administration of Jelmyto® is Efficient for Doctors and Well Tolerated by PatientsSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:URGN CUSIPN/A CIK1668243 Webwww.urogen.com Phone(646) 768-9780FaxN/AEmployees195Year FoundedN/ACompany Calendar Last Earnings5/10/2022Today7/05/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$19.00 High Stock Price Forecast$26.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+134.3%Consensus RatingModerate Buy Rating Score (0-4)2.66666666666667 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,820,000.00 Net Margins-209.30% Pretax Margin-206.02% Return on Equity-572.49% Return on Assets-78.96% Debt Debt-to-Equity RatioN/A Current Ratio8.41 Quick Ratio8.16 Sales & Book Value Annual Sales$48.04 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.61 per share Price / Book1.76Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable Beta0.98 UroGen Pharma Frequently Asked Questions Should I buy or sell UroGen Pharma stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UroGen Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" UroGen Pharma stock. View analyst ratings for UroGen Pharma or view top-rated stocks. What is UroGen Pharma's stock price forecast for 2022? 3 equities research analysts have issued 1-year price targets for UroGen Pharma's shares. Their URGN stock forecasts range from $11.00 to $26.00. On average, they anticipate UroGen Pharma's stock price to reach $19.00 in the next year. This suggests a possible upside of 134.3% from the stock's current price. View analysts' price targets for UroGen Pharma or view top-rated stocks among Wall Street analysts. How has UroGen Pharma's stock price performed in 2022? UroGen Pharma's stock was trading at $9.51 on January 1st, 2022. Since then, URGN shares have decreased by 14.7% and is now trading at $8.11. View the best growth stocks for 2022 here. When is UroGen Pharma's next earnings date? UroGen Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for UroGen Pharma. How were UroGen Pharma's earnings last quarter? UroGen Pharma Ltd. (NASDAQ:URGN) announced its quarterly earnings results on Tuesday, May, 10th. The company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.36) by $0.11. The company had revenue of $13.56 million for the quarter, compared to analysts' expectations of $15.62 million. UroGen Pharma had a negative net margin of 209.30% and a negative trailing twelve-month return on equity of 572.49%. View UroGen Pharma's earnings history. Who are UroGen Pharma's key executives? UroGen Pharma's management team includes the following people: Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 60, Pay $1.25M) (LinkedIn Profile)Mr. Jason Drew Smith, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50, Pay $616.34k) (LinkedIn Profile)Dr. Mark P. Schoenberg M.D., Chief Medical Officer (Age 64, Pay $579.5k)Mr. Dong Kim, Chief Financial Officer (Age 45)Vincent I. Perrone, Sr. Director of Investor RelationsEric Van Zanten, Sr. Director of CommunicationsDr. Sari Prutchi-Sagiv Ph.D., Marketing DirectorDr. Marina Konorty, Exec. VP of R&D and Technical OperationsMr. Jeffrey Bova M.B.A., Chief Commercial OfficerMr. James Ottinger R.ph., Exec. VP of Regulatory Affairs & Quality Who are some of UroGen Pharma's key competitors? Some companies that are related to UroGen Pharma include Abliva AB (publ) (NEVPF), Acusphere (ACUS), ADC Therapeutics (ADCT), Addex Therapeutics (ADDXF), Aeolus Pharmaceuticals (AOLS), Affymax (AFFY), Alseres Pharmaceuticals (ALSE), American Oriental Bioengineering (AOBI), Anthera Pharmaceuticals (ANTH), Aoxing Pharmaceutical (AOXG), ARYx Therapeutics (ARYX), AtheroNova (AHROQ), AXM Pharma (AXMP), Basilea Pharmaceutica (BPMUF) and Biostar Pharmaceuticals (BSPM). View all of URGN's competitors. What other stocks do shareholders of UroGen Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other UroGen Pharma investors own include Sorrento Therapeutics (SRNE), Micron Technology (MU), OPKO Health (OPK), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Exelixis (EXEL), (KITE) (KITE), Syndax Pharmaceuticals (SNDX), AbbVie (ABBV) and Aytu BioPharma (AYTU). When did UroGen Pharma IPO? (URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers. What is UroGen Pharma's stock symbol? UroGen Pharma trades on the NASDAQ under the ticker symbol "URGN." How do I buy shares of UroGen Pharma? Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is UroGen Pharma's stock price today? One share of URGN stock can currently be purchased for approximately $8.11. How many employees does UroGen Pharma have? UroGen Pharma employs 195 workers across the globe. How can I contact UroGen Pharma? UroGen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The official website for UroGen Pharma is www.urogen.com. The company can be reached via phone at (646) 768-9780 or via email at kate.bechtold@urogen.com. This page (NASDAQ:URGN) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
